Two-Year Follow-Up Study of Patients with Neovascular Age-Related Macular Degeneration Undergoing Anti-VEGF Treatment during the COVID-19 Pandemic.

Publication date: Feb 01, 2024

regular intravitreal anti-vascular endothelial growth factor (VEGF) treatment is crucial for patients with neovascular age-related macular degeneration (nAMD), and delayed treatment can exacerbate disease progression. we compared the outcomes of on-time versus delayed intravitreal anti-VEGF treatment for patients with nAMD. This study was conducted during the coronavirus disease 2019 (COVID-19) pandemic with a 2-year follow-up period. The best-corrected visual acuity (BCVA) and anatomical findings were evaluated before the pandemic, during the pandemic, and at 6-, 12-, 18-, and 24-months post-pandemic. The delayed and on-time groups comprised 54 and 72 patients, respectively. After the pandemic, the injection interval increased by 0. 65 +/- 1. 51 months (p = 0. 003), with 22. 2% of the patients in the delayed group switching to the treat-and-extended regimen (p < 0. 001). The delayed group showed greater mean BCVA deterioration (p = 0. 027) and central subfield thickness (p = 0. 037) at 6 months and worse maximum subretinal fluid height (p = 0. 022) at 18 months than the on-time group. No difference was observed between the groups in the second year. the negative effects of delaying anti-VEGF treatment because of the COVID-19 pandemic can be ameliorated by changing the treatment regimen and shortening treatment intervals.

Open Access PDF

Concepts Keywords
Coronavirus COVID-19
Endothelial macular degeneration


Type Source Name
disease MESH Age-Related Macular Degeneration
disease MESH COVID-19 Pandemic
disease MESH disease progression
disease VO time
disease VO injection
drug DRUGBANK Methyldopa
disease MESH blindness
disease MESH choroidal neovascularization
disease MESH bleeding
disease VO Prn
drug DRUGBANK Coenzyme M
disease MESH diabetic retinopathy
disease MESH infection
disease MESH visual impairment
disease VO Gap
disease MESH emergency
disease VO monthly
disease MESH scar
disease MESH geographic atrophy
disease VO anatomical structure
disease MESH retinal vein occlusion
disease MESH glaucoma
disease MESH myopia
disease MESH cataract
disease IDO process
disease VO ANOVA
disease VO USA

Original Article

(Visited 1 times, 1 visits today)